Long-acting amylin analog · Also known as CagriSema (combination with semaglutide)
A long-acting synthetic analog of amylin, a hormone co-secreted with insulin that promotes satiety. Studied both as monotherapy and in combination with semaglutide (CagriSema), where it has produced over 20% average weight loss.
Developed by Novo Nordisk, cagrilintide targets the amylin pathway, which is distinct from GLP-1 signaling. When combined with semaglutide as CagriSema, it achieved weight loss results exceeding either agent alone. Novo Nordisk submitted an NDA to the FDA in December 2025, making CagriSema the first GLP-1 plus amylin combination to seek approval for weight management.
Amylin is a hormone released alongside insulin from pancreatic beta cells after meals. It works in the brain's area postrema and other hindbrain regions to produce feelings of fullness, slow gastric emptying, and suppress postprandial glucagon release. Natural amylin is cleared from the body in minutes. Cagrilintide is engineered with fatty acid acylation to extend its half-life, enabling once-weekly dosing.
Because amylin and GLP-1 act through different receptor systems and brain regions, combining cagrilintide with semaglutide produces additive appetite suppression. The amylin pathway primarily signals through hindbrain satiety centers, while GLP-1 acts on hypothalamic and reward circuits. Together, they reduce hunger more effectively than either pathway alone.
0.25 mg/week
Weeks 1-4 (titrate every 4 weeks)2.4 mg/week
After titration (typically 16-20 weeks)Most side effects tend to improve as your body adjusts.